Skip to main content
  • Sign in
    Welcome !
    My account
    Logout

PLUS THERAPEUTICS, INC. (PSTV) Stock Forecast 2025 - AI Price Prediction & Analysis

PLUS THERAPEUTICS, INC. (PSTV) AI Stock Price Forecast & Investment Analysis

PLUS THERAPEUTICS, INC. Stock Price Chart and Technical Analysis

Loading PLUS THERAPEUTICS, INC. interactive price chart and technical analysis...

PLUS THERAPEUTICS, INC. (PSTV) - Comprehensive Stock Analysis & Investment Research

Deep dive into PLUS THERAPEUTICS, INC.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about PLUS THERAPEUTICS, INC., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For PLUS THERAPEUTICS, INC.: PLUS THERAPEUTICS, INC. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

PLUS THERAPEUTICS, INC. (Stock Symbol: PSTV) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 19 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing PLUS THERAPEUTICS, INC.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For PLUS THERAPEUTICS, INC.:

Market Capitalization: $12 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -122.5% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for PLUS THERAPEUTICS, INC. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For PLUS THERAPEUTICS, INC.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for PLUS THERAPEUTICS, INC. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: PLUS THERAPEUTICS, INC.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For PLUS THERAPEUTICS, INC.: Market positioning analysis based on available financial and operational metrics.

PLUS THERAPEUTICS, INC. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 20.8% gross margin, indicating strong pricing power and operational efficiency.

PLUS THERAPEUTICS, INC. (PSTV) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for PLUS THERAPEUTICS, INC. stock analysis.

Loading PLUS THERAPEUTICS, INC. comprehensive fundamental analysis and insider trading data...

Deep dive into PLUS THERAPEUTICS, INC.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if PLUS THERAPEUTICS, INC. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For PLUS THERAPEUTICS, INC.: With a P/E ratio of -0.29, the market sees the stock as potentially undervalued.

P/E Ratio -0.29x
P/B Ratio -0.53x
Market Cap $12M
Dividend Yield 17.28%
EPS $-4.34
Book Value/Share $-1.39
Revenue/Share $0.01
FCF/Share $-1.15
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently PLUS THERAPEUTICS, INC. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For PLUS THERAPEUTICS, INC.: An ROE of -122.5% indicates room for improvement in shareholder value creation.

ROE -122.5%
ROA -69.1%
ROIC -73.5%
Gross Margin 20.8%
Operating Margin -2004.8%
Net Margin -1354.7%
EBT Margin -46.9%
Tax Rate 34.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess PLUS THERAPEUTICS, INC.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For PLUS THERAPEUTICS, INC.: A current ratio of 4.49 indicates strong liquidity.

Current Ratio 4.49x
Quick Ratio 4.31x
D/E Ratio 0.34x
Financial Leverage 1.67x
Interest Coverage -15.8x
Working Capital $1M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal PLUS THERAPEUTICS, INC.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For PLUS THERAPEUTICS, INC.: Free cash flow of $-12M indicates cash challenges that need attention.

Operating Cash Flow $-11M
Free Cash Flow $-12M
Capital Spending $-1M
OCF Growth YoY 280.0%
FCF Growth YoY 9.7%
FCF/Sales -85.4%
CapEx/Sales 162.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively PLUS THERAPEUTICS, INC. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For PLUS THERAPEUTICS, INC.: An asset turnover of 0.02x suggests room for improvement in asset utilization.

Asset Turnover 0.02x
Receivables Turnover 0.5x
Inventory Turnover 0.4x
Fixed Assets Turnover 0.1x
Days Sales Outstanding 704 days
Days Inventory 975 days
Payables Period 321 days
Cash Conversion Cycle 666 days
Understanding Financial Statement Data

What these metrics mean: Key figures from PLUS THERAPEUTICS, INC.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For PLUS THERAPEUTICS, INC.:

Income Statement ($ Millions)
Operating Income $-14M
Net Income $-12M
R&D Expense $11M
SG&A Expense $76M
Cost of Goods Sold $0M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 90%
Cash & Short-term Investments 87%
Total Liabilities 40%
Short-term Debt 7%
Accounts Receivable 0%
Inventory 0%
Dividend & Shareholder Information
Dividends Per Share $0.42
Payout Ratio 5.6%
Shares Outstanding 17M
Growth Metrics (YoY)
EPS Growth -361.7%

Latest PLUS THERAPEUTICS, INC. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting PLUS THERAPEUTICS, INC. (PSTV) stock price and investment outlook.

📰 We are currently updating our news feed for PLUS THERAPEUTICS, INC.. Check back soon for the latest market analysis and company updates.

PLUS THERAPEUTICS, INC. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of PLUS THERAPEUTICS, INC. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $24M x 2.8x
AEMD Unlock Forecast - 30 Days FREE Trial $3M -0.1x 0.7x
AFIB Unlock Forecast - 30 Days FREE Trial $0M 0.0x -0.4x
ALUR Unlock Forecast - 30 Days FREE Trial $17M -0.4x -0.3x
AMIX Unlock Forecast - 30 Days FREE Trial $4M x 0.5x
ANGO Unlock Forecast - 30 Days FREE Trial $447M -1.4x 2.4x
ANIK Unlock Forecast - 30 Days FREE Trial $129M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $1831M -198.2x 4.4x
APYX Unlock Forecast - 30 Days FREE Trial $76M -3.5x 10.5x
ARAY Unlock Forecast - 30 Days FREE Trial $138M -9.9x 2.8x
ATEC Unlock Forecast - 30 Days FREE Trial $2324M -7.4x 97.8x
ATRC Unlock Forecast - 30 Days FREE Trial $1750M -39.6x 3.8x
AVGR Unlock Forecast - 30 Days FREE Trial $2M -1.3x 0.4x
AVHHL Unlock Forecast - 30 Days FREE Trial $24M x x
BAX Unlock Forecast - 30 Days FREE Trial $12521M -94.9x 1.7x
BBNX Unlock Forecast - 30 Days FREE Trial $1081M x 3.6x
BDX Unlock Forecast - 30 Days FREE Trial $54993M 34.7x 2.2x
BEAT Unlock Forecast - 30 Days FREE Trial $46M -5.7x 11.0x
BEATW Unlock Forecast - 30 Days FREE Trial $15M x 3.2x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.4x
BLAC Unlock Forecast - 30 Days FREE Trial $12M x -2.1x
BLACR Unlock Forecast - 30 Days FREE Trial $1M x -0.2x
BLACU Unlock Forecast - 30 Days FREE Trial $14M x -2.4x
BLACW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
BSX Unlock Forecast - 30 Days FREE Trial $157140M 62.7x 7.0x
BTCY Unlock Forecast - 30 Days FREE Trial $10M -2.7x -0.1x
BVS Unlock Forecast - 30 Days FREE Trial $617M -18.3x 3.8x
CARL Unlock Forecast - 30 Days FREE Trial $-18M x x
CERS Unlock Forecast - 30 Days FREE Trial $235M -13.8x 4.2x
CLPT Unlock Forecast - 30 Days FREE Trial $314M -23.5x 15.9x
CODX Unlock Forecast - 30 Days FREE Trial $11M -0.7x 0.3x
CTCX Unlock Forecast - 30 Days FREE Trial $5M -0.2x -1.2x
CTCXW Unlock Forecast - 30 Days FREE Trial $1M x -0.2x
CTSO Unlock Forecast - 30 Days FREE Trial $64M -1.8x 4.4x
CVRX Unlock Forecast - 30 Days FREE Trial $208M -5.5x 3.6x
DCTH Unlock Forecast - 30 Days FREE Trial $465M 208.2x 4.4x
DHAI Unlock Forecast - 30 Days FREE Trial $10M x -0.3x
DHAIW Unlock Forecast - 30 Days FREE Trial $1M x 0.0x
DRIO Unlock Forecast - 30 Days FREE Trial $30M 0.6x 0.4x
DRTS Unlock Forecast - 30 Days FREE Trial $306M x 3.5x
DXCM Unlock Forecast - 30 Days FREE Trial $31972M 55.9x 12.4x
EBRCZ Unlock Forecast - 30 Days FREE Trial $246M x 5.0x
EMBC Unlock Forecast - 30 Days FREE Trial $572M 15.8x -0.8x
FEMY Unlock Forecast - 30 Days FREE Trial $12M -1.4x 8.1x
FNA Unlock Forecast - 30 Days FREE Trial $1098M -15.4x 8.4x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 13.6x
GCTK Unlock Forecast - 30 Days FREE Trial $2M 0.9x -0.5x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 27.9x
GKOS Unlock Forecast - 30 Days FREE Trial $5205M -46.3x 6.8x
GMED Unlock Forecast - 30 Days FREE Trial $8161M 22.9x 1.9x
GUTS Unlock Forecast - 30 Days FREE Trial $88M x 13.8x
HAE Unlock Forecast - 30 Days FREE Trial $3541M 26.1x 4.3x
HRGN Unlock Forecast - 30 Days FREE Trial $28M x 36.7x
IART Unlock Forecast - 30 Days FREE Trial $1179M 200.2x 1.1x
ICAD Unlock Forecast - 30 Days FREE Trial $106M -3.1x 3.5x
ICCM Unlock Forecast - 30 Days FREE Trial $60M x 20.9x
ICU Unlock Forecast - 30 Days FREE Trial $8M -1.1x 13.3x
ICUCW Unlock Forecast - 30 Days FREE Trial $0M x -0.1x
ICUI Unlock Forecast - 30 Days FREE Trial $3248M -49.8x 1.6x
IDXG Unlock Forecast - 30 Days FREE Trial $22M 4.2x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $30M x 6.8x
IINNW Unlock Forecast - 30 Days FREE Trial $8M x 2.0x
INBS Unlock Forecast - 30 Days FREE Trial $11M -0.3x 3.6x
INFU Unlock Forecast - 30 Days FREE Trial $216M 42.6x 4.0x
INSP Unlock Forecast - 30 Days FREE Trial $2323M 43.7x 3.4x
IRMD Unlock Forecast - 30 Days FREE Trial $924M 44.7x 9.8x
IRTC Unlock Forecast - 30 Days FREE Trial $5984M -20.2x 57.7x
IVF Unlock Forecast - 30 Days FREE Trial $1M x 0.3x
KIDS Unlock Forecast - 30 Days FREE Trial $488M -20.7x 1.4x
KMTS Unlock Forecast - 30 Days FREE Trial $873M x x
KRMD Unlock Forecast - 30 Days FREE Trial $188M -19.8x 11.4x
LMAT Unlock Forecast - 30 Days FREE Trial $0M 58.7x 0.0x
LNSR Unlock Forecast - 30 Days FREE Trial $58M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $140M -0.6x 17.7x
LUNG Unlock Forecast - 30 Days FREE Trial $71M -4.3x 1.0x
LYRA Unlock Forecast - 30 Days FREE Trial $524M -0.1x 135.2x
MBOT Unlock Forecast - 30 Days FREE Trial $92M -1.3x 3.2x
MCAG Unlock Forecast - 30 Days FREE Trial $22M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $21M x -9.9x
MDAI Unlock Forecast - 30 Days FREE Trial $69M -1.3x -42.3x
MDAIW Unlock Forecast - 30 Days FREE Trial $9M x -2.1x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.8x 13.4x
MDXG Unlock Forecast - 30 Days FREE Trial $1030M 32.0x 4.8x
MGRM Unlock Forecast - 30 Days FREE Trial $206M -10.7x 23.9x
MHUA Unlock Forecast - 30 Days FREE Trial $11M x 0.1x
MMM Unlock Forecast - 30 Days FREE Trial $84491M 21.5x 19.7x
MMSI Unlock Forecast - 30 Days FREE Trial $5586M 46.9x 3.8x
MODD Unlock Forecast - 30 Days FREE Trial $38M -2.1x 2.2x
NARI Unlock Forecast - 30 Days FREE Trial $4677M -51.9x 10.8x
NAYA Unlock Forecast - 30 Days FREE Trial $2M -0.3x 0.2x
NEPH Unlock Forecast - 30 Days FREE Trial $39M -20.3x 2.0x
NMTC Unlock Forecast - 30 Days FREE Trial $40M -1.7x 4.8x
NPCE Unlock Forecast - 30 Days FREE Trial $322M -10.4x 16.5x
NSPR Unlock Forecast - 30 Days FREE Trial $122M -4.3x 6.0x
NURO Unlock Forecast - 30 Days FREE Trial $9M -0.5x 0.7x
NVAC Unlock Forecast - 30 Days FREE Trial $69M 84.3x -13.6x
NVACR Unlock Forecast - 30 Days FREE Trial $1M x -0.1x
NVACW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
NVCR Unlock Forecast - 30 Days FREE Trial $1344M -20.8x 3.9x
NVNO Unlock Forecast - 30 Days FREE Trial $87M -2.0x 2.3x
NVRO Unlock Forecast - 30 Days FREE Trial $221M -2.1x 1.0x
NXGL Unlock Forecast - 30 Days FREE Trial $18M -6.8x 4.0x
NXGLW Unlock Forecast - 30 Days FREE Trial $3M x 0.7x
OBIO Unlock Forecast - 30 Days FREE Trial $118M -3.4x 2.0x
OFIX Unlock Forecast - 30 Days FREE Trial $580M -5.8x 1.3x
OSRH Unlock Forecast - 30 Days FREE Trial $18M x 0.2x
OSUR Unlock Forecast - 30 Days FREE Trial $241M 17.1x 0.6x
PAVM Unlock Forecast - 30 Days FREE Trial $20M 0.3x 0.5x
PAVMZ Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
PDEX Unlock Forecast - 30 Days FREE Trial $128M 14.3x 3.5x
PEN Unlock Forecast - 30 Days FREE Trial $11258M 76.2x 8.7x
PETV Unlock Forecast - 30 Days FREE Trial $18M -1.4x 12.0x
PLSE Unlock Forecast - 30 Days FREE Trial $1016M -2.6x 8.6x
PODD Unlock Forecast - 30 Days FREE Trial $24924M 105.6x 17.0x
PRCT Unlock Forecast - 30 Days FREE Trial $2128M -45.4x 5.5x
PROF Unlock Forecast - 30 Days FREE Trial $124M x 3.2x
PSTV Unlock Forecast - 30 Days FREE Trial $12M -0.3x -0.5x
PYPD Unlock Forecast - 30 Days FREE Trial $54M x 2.6x
RCEL Unlock Forecast - 30 Days FREE Trial $111M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $47M x 17.4x
RMD Unlock Forecast - 30 Days FREE Trial $41136M 29.4x 6.9x
RSMDF Unlock Forecast - 30 Days FREE Trial $2450M 1.8x 0.4x
RTGN Unlock Forecast - 30 Days FREE Trial $66M x x
RVP Unlock Forecast - 30 Days FREE Trial $24M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $192M -3.7x 2.7x
SIBN Unlock Forecast - 30 Days FREE Trial $701M -14.3x 4.1x
SINT Unlock Forecast - 30 Days FREE Trial $7M -0.5x 1.1x
SKIN Unlock Forecast - 30 Days FREE Trial $288M -1.8x 3.9x
SNOA Unlock Forecast - 30 Days FREE Trial $8M -5.6x 1.9x
SNWV Unlock Forecast - 30 Days FREE Trial $308M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $12758M 33.6x 3.5x
SRDX Unlock Forecast - 30 Days FREE Trial $432M -79.3x 3.9x
SRTS Unlock Forecast - 30 Days FREE Trial $53M 31.6x 1.0x
SSII Unlock Forecast - 30 Days FREE Trial $1535M x 37.9x
SSKN Unlock Forecast - 30 Days FREE Trial $7M -8.0x 24.1x
STIM Unlock Forecast - 30 Days FREE Trial $248M -1.0x 9.1x
STME Unlock Forecast - 30 Days FREE Trial $12M x x
STSS Unlock Forecast - 30 Days FREE Trial $10M -2.5x 0.7x
STSSW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
SYK Unlock Forecast - 30 Days FREE Trial $140684M 42.0x 12.0x
TCMD Unlock Forecast - 30 Days FREE Trial $319M 21.1x 1.6x
TELA Unlock Forecast - 30 Days FREE Trial $72M -1.8x 7.9x
TFX Unlock Forecast - 30 Days FREE Trial $5876M 30.6x 1.4x
TLSI Unlock Forecast - 30 Days FREE Trial $191M -3.6x -5.6x
TLSIW Unlock Forecast - 30 Days FREE Trial $66M x -1.9x
TMCI Unlock Forecast - 30 Days FREE Trial $628M -7.5x 6.0x
TNDM Unlock Forecast - 30 Days FREE Trial $835M -17.1x 6.3x
TNON Unlock Forecast - 30 Days FREE Trial $9M -0.3x 1.3x
TNONW Unlock Forecast - 30 Days FREE Trial $0M x 0.0x
TTOO Unlock Forecast - 30 Days FREE Trial $4M 0.0x -0.3x
UFPT Unlock Forecast - 30 Days FREE Trial $1757M 44.7x 4.9x
USAQ Unlock Forecast - 30 Days FREE Trial $2M x x
UTMD Unlock Forecast - 30 Days FREE Trial $208M 16.6x 1.8x
VERO Unlock Forecast - 30 Days FREE Trial $5M 0.0x 2.2x
VTAK Unlock Forecast - 30 Days FREE Trial $3M 0.0x 0.3x
VVOS Unlock Forecast - 30 Days FREE Trial $21M -0.5x 2.8x
WST Unlock Forecast - 30 Days FREE Trial $18349M 37.6x 6.3x
XAIR Unlock Forecast - 30 Days FREE Trial $303M -0.3x 22.3x
XTNT Unlock Forecast - 30 Days FREE Trial $93M -478.8x 1.9x

Frequently Asked Questions - PLUS THERAPEUTICS, INC. Stock Forecast

How accurate are PLUS THERAPEUTICS, INC. stock predictions?

Our AI model demonstrates 14% historical accuracy for PSTV predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence PLUS THERAPEUTICS, INC. stock price forecasts?

Our analysis considers PLUS THERAPEUTICS, INC.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is PLUS THERAPEUTICS, INC. a good investment in 2025?

Based on our AI analysis, PLUS THERAPEUTICS, INC. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are PLUS THERAPEUTICS, INC. forecasts updated?

PLUS THERAPEUTICS, INC. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced PLUS THERAPEUTICS, INC. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for PLUS THERAPEUTICS, INC. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...